Specific Antitumor Immunity and its Role in Host Resistance to Tumors

  • Robert W. Baldwin
Part of the Cancer Treatment and Research book series (CTAR, volume 14)

Abstract

The repertoire of tumors in which there is conclusive evidence for the expression of antigens which can be manipulated to produce tumor rejection responses has grown considerably since the early studies reported some 25 to 30 years ago with 3-methylcholanthrene (MCA)-induced rodent sarcomas [1–3]. It now includes tumors of many types such as carcinomas and sarcomas induced with a broad spectrum of chemical carcinogens [4] many of these belonging to the classes (polycyclic hydrocarbons, nitrosamines, aromatic amines and aminoazo dyes) which are known, or suspected to be, human carcinogens [5], Rodent tumors induced with DNA- and RNA- containing viruses also express antigens able to induce tumour rejection responses in the host [6, 7].

Keywords

Recombination Fractionation Sarcoma Interferon Cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Foley EJ: Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13: 835–837, 1953.PubMedGoogle Scholar
  2. 2.
    Baldwin RW: Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of implanted tumours. Brit J Cancer 9: 652–657, 1955.PubMedCrossRefGoogle Scholar
  3. 3.
    Prehn RT, Main JM: Immunity to methylcholathrene induced sarcomas. J Natl Cancer Inst 18: 769–778, 1957.PubMedGoogle Scholar
  4. 4.
    Baldwin RW, Price MR: Neoantigen expression in chemical carcinogenesis. In: Cancer: A comprehensive treatise: 1. Etiology: Chemical and physical carcinogenesis, Becker FF (ed). New York: Plenum Press, 1982, pp 507–548.Google Scholar
  5. 5.
    IACR Working Group: An evaluation of chemicals and industrial processes associated with cancer in humans based on human and animal data. IACR Monogr Vols 1–20. Cancer Res 40: 1–12, 1980.Google Scholar
  6. 6.
    Kurth R, Fenyo EM, Klein E, Essex M: Cell surface antigens induced by RNA tumour viruses. Nature 279: 197–201, 1979.PubMedCrossRefGoogle Scholar
  7. 7.
    Ito Y: Immunology of DNA virus-induced tumours. In: Immunology 80, Fougereau M, Dauset J (eds). London: Academic Press, 1980, pp 668–679.Google Scholar
  8. 8.
    Terry WD, Rosenberg SA: Immunotherapy of human cancer. Amsterdam: Elsevier, pp 1–520, 1982.Google Scholar
  9. 9.
    Lennox ES: The antigens of chemically induced tumours. In: Immunology 80, Fougereau M, Dausset J (eds). London: Academic Press, 1980, pp 659–667.Google Scholar
  10. 10.
    Baldwin RW, Embleton MJ, Gunn B, Price MR, Reeve JG: Neoantigens on tumours induced by chemical carcinogens: Regulation and characterisation. In: Genes and tumor genes, Winnacker E, Schoene H-H (eds). New York: Raven Press, 1982, pp 109–114.Google Scholar
  11. 11.
    Hewitt HB: The choice of animal tumors for experimental studies of cancer therapy. Adv Cancer Res 27: 149–200, 1979.CrossRefGoogle Scholar
  12. 12.
    Baldwin RW, Embleton MJ, Pimm MV: Host response to spontaneous rat tumours. In: Antiviral mechanisms in the control of neoplasia, Chandra P (ed). New York: Plenum Press, 1979, pp 333–353.Google Scholar
  13. 13.
    Baldwin RW, Embleton MJ: Immunology of spontanously acising rat mammary adenocarcinomas. Int J Cancer 4: 430–439, 1969.PubMedCrossRefGoogle Scholar
  14. 14.
    Baldwin RW, Embleton MJ, Pimm MV: Neoantigens in chemical carcinogenesis. In: Carcinogens: Identity and mechanisms of action, Griffin AC, Shaw CR (eds). New York: Raven Press, 1979, pp 365–379.Google Scholar
  15. 15.
    Baldwin RW, Embleton MJ: Tumour-specific antigens in 2-acetylaminofluorene-induced rat hepatomas and related tumors. Israel J Med Sci 7: 144–153, 1971.PubMedGoogle Scholar
  16. 16.
    Baldwin RW, Embleton MJ: Immunology of 2-acetylaminofluorene-induced rat mammary adenocarcinomas. Int J Cancer 4: 47–53, 1969.PubMedCrossRefGoogle Scholar
  17. 17.
    Boon T, Von Snick J, Van Pel A, Uyttenhove C, Marchand M: Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815: II. T lymphocyte-mediated cytolysis. J Exp Med 152: 1184–1193, 1980.PubMedCrossRefGoogle Scholar
  18. 18.
    Baldwin RW, Klein G: Escape of tumor cells from immune controls. Cancer Res 42:1608–1609, 1982. 0Google Scholar
  19. 19.
    Wheelock EF, Weinhold KJ, Levich J: The tumor dormant state. Adv Cancer Res 34: 107–140, 1981.PubMedCrossRefGoogle Scholar
  20. 20.
    Hellström KE, Hellström I, Nelson K: Antigen specific suppressor (blocking) factors in tumor immunity. In: Pathological membranes, Nowotny A (ed). New York: Plenum Press. 1982, In press.Google Scholar
  21. 21.
    Naor D: Suppressor cells: Permitters and promoters of malignancy. Adv Cancer Res 29: 45–125, 1979.PubMedCrossRefGoogle Scholar
  22. 22.
    North RJ, Dye ES, Mills CD, Chandler JP: Modulation of antitumor immunity: Immuno- biological approaches. Seminars Immunopathol 512: 193–220, 1982.Google Scholar
  23. 23.
    Baldwin RW: Mechanisms of immunity in cancer. Pathobiol Annual Ioachim HL (ed). New York: Raven Press, 1981, pp 155–175.Google Scholar
  24. 24.
    Ozer H: Tumor immunity and escape mechanisms in humans. In: Immunological approaches to cancer therapeutics, Mihich E (ed). New York: Wiley-Interscience, pp 39–73.Google Scholar
  25. 25.
    Pimm MV, Baldwin RW: Antigenic differences between primary methylcholanthrene- induced rat sarcomas and post-surgical recurrences. Int J Cancer 20: 37–43, 1977.PubMedCrossRefGoogle Scholar
  26. 26.
    Pimm MV, Embleton MJ, Baldwin RW: Multiple antigenic specificities within primary 3-methylcholanthrene-induced rat sarcomas and metastases. Int J Cancer 25: 621–629, 1980.PubMedCrossRefGoogle Scholar
  27. 27.
    Schmitt M, Daynes RA: Heterogeneity of tumorigenicity phenotype in murine tumors. Transplant 33: 387–392, 1982.CrossRefGoogle Scholar
  28. 28.
    Schirrmacher V, Bosslet K: Clonal analysis of expression of tumor-associated transplantation antigens and metastatic capacity. Cancer Immunol Immunother 1311: 62–68, 1982.Google Scholar
  29. 29.
    Baldwin RW, Pimm MV: Human tumor xenograft in athymic nude mice: Non-specific host rejection responses. In: Immunodeficient animals for cancer research, S. Sparrow (ed). London: Macmillan, 1980, pp 125–133.Google Scholar
  30. 30.
    Baldwin RW, Byers VS, Hannant D, Jones JA, Pimm MV, Price MR: Cellular interactions modulating host resistance to tumours. Recent Res in Cancer Res 80. Berlin: Springer-Verlag, 1982, pp 338–345.Google Scholar
  31. 31.
    Brooks CG, Wayner EA, Webb PJ, Dixon Gray J, Kenwrick S, Baldwin RW: The specificity of rat natural killer cells and cytotoxic macrophages on solid tumor-derived target cells and selected variants. J Immunol 127: 2477–2483, 1981.PubMedGoogle Scholar
  32. 32.
    Berke G: Interaction of cytotoxic T lymphocytes and target cells. Prog Allergy 27. Basel: Karger, 1980, pp 69–133.Google Scholar
  33. 33.
    Plata F: Specificity studies of cytolitic T lymphocytes against murine leukemia virus- induced tumors. J Exp Med 155: 1050–1062, 1982.PubMedCrossRefGoogle Scholar
  34. 34.
    Yamauchi K, Fujito S, Tada T: Differential activation of cytotoxic and suppressor T cells against syngeneic tumors in the mouse. J Immunol 123: 1653–1658, 1979.PubMedGoogle Scholar
  35. 35.
    Cantor H, Boyse EA: Regulation of cellular and humoral immune responses by T cell subclasses. Cold Spring Harbor Symp 41: 23–31, 1977.Google Scholar
  36. 36.
    McKenzie IFC, Potter T: Murine lymphocyte surface antigens. Adv Immunol 27: 79–338, 1979.Google Scholar
  37. 37.
    Nelson M, Nelson DS, McKenzie IFC, Blanden RV: Thy and Ly markers on lymphocytes initiating tumor rejection. Cell Immunol 60: 34–42, 1981.PubMedCrossRefGoogle Scholar
  38. 38.
    Greenberg PD, Cheever MA, Fefer A: Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune Lyt 1+ 2- lymphocytes. J Exp Med 154: 952–963, 1981.PubMedCrossRefGoogle Scholar
  39. 39.
    Drebin JA, Perry LL, Carter R and Greene MI: Regulation of the immune response to antigens on the malignant cell surface. Seminars in Immunopathol 512: 175–192, 1982.Google Scholar
  40. 40.
    Fernandez-Cruz E, Woda BA, Feldman JD: Elimination of syngeneic sarcoma in rats by a subset of T lymphocytes. J Exp Med 52: 823–841, 1980.CrossRefGoogle Scholar
  41. 41.
    Fernandez-Cruz E, Gilman SC, Feldman JD: Immunotherapy of a chemically-induced sarcoma in rats: Characterization of the effector T cell subset and nature of suppression. J Immunol 128: 1112–1117, 1982.PubMedGoogle Scholar
  42. 42.
    Loveland BE, Hogarth PM, Ceredig Rh, McKenzie IFC: Cells mediating graft rejection in the mouse: I. Lyt-1 cells mediate skin graft rejection. J Exp Med 153: 1044–1057, 1981.PubMedCrossRefGoogle Scholar
  43. 43.
    Loveland BE, McKenzie IFC: Which cells cause graft rejection? Transplantation 33: 217–221, 1982.PubMedGoogle Scholar
  44. 44.
    Dallman MJ, Mason DW: Role of thymus-derived and thymus-independent cells in murine skin allograft rejection. Transplantation 33: 221–223, 1982.PubMedCrossRefGoogle Scholar
  45. 45.
    Cantrell DA, Robins RA, Baldwin RW: Rat lymphocyte subset: Cellular requirements for the generation of T-cell growth factor. Cell Immunol 70: 367–372, 1982.PubMedCrossRefGoogle Scholar
  46. 46.
    Sonnenfeld G, Mandel AD, Merigan TC: In vitro production and cellular origin of murine type II interferon. Immunology 36: 883–890, 1979.PubMedGoogle Scholar
  47. 47.
    O’Malley JA, Nussbaum-Blumenson A, Sheedy D, Crossmayer BJ, Ozer H: Identification of the T cell subset that produces human y interferon. J Immunol 128: 2522–2526, 1982.PubMedGoogle Scholar
  48. 48.
    Klein E: Lymphocyte mediated lysis of tumor cells in vitro: Antigen restricted clonal and unrestricted polyclonal effects. Springer Seminars in Immunopathol 512: 147–159, 1982.Google Scholar
  49. 49.
    Kripke ML: Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 53: 1333–1336, 1976.Google Scholar
  50. 50.
    Berendt MJ, North RJ: T cell mediated suppression of antitumor immunity: An explanation for progressive growth of an immunogenic tumor. J Exp Med 151: 69–80, 1980.PubMedCrossRefGoogle Scholar
  51. 51.
    Dye ES, North RJ: T cell mediated suppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. J Exp Med 154: 1033–1042, 1981.PubMedCrossRefGoogle Scholar
  52. 52.
    Price MR, Preston VE, Robins RA, Zöller M, Baldwin RW: Induction of immunity to chemically induced tumours be cellular or soluble antigens. Cancer Immunol Immunother 3: 247–252, 1978.CrossRefGoogle Scholar
  53. 53.
    Price MR, Baldwin RW: Shedding of tumor cell surface antigens. In: Dynamic aspects of cell surface organisation, Poste G, Nicolson GL (eds). Amsterdam: Elsevier, North Holland, 1977, pp 423–471.Google Scholar
  54. 54.
    Baldwin RW, Byers VS, Robins RA: Circulating imune complexes in cancer: Characterization and potential as tumour markers. Behring Inst Mitt 64: 63–77, 1979.Google Scholar
  55. 55.
    Baldwin RW: Immunotherapy of tumors. In: Cancer chemotherapy annual 3, Pinedo HM (ed). Amsterdam: Excerpta Medica, 1981, pp 178–202.Google Scholar
  56. 56.
    Baldwin RW: Specific and non-specific cellular interactions modulating host resistance to tumors. In: Fundamental mechanisms in human cancer immunology, Saunders JP, Daniels JC, Serrou B, Rosenfeld C, Denney CB (eds). Amsterdam: Elsevier, North Holland, 1981, pp 167–180.Google Scholar
  57. 57.
    Baldwin RW, Pimm MV: BCG immunotherapy of a rat sarcoma. Br J Cancer 28: 281–287, 1973.PubMedCrossRefGoogle Scholar
  58. 58.
    Hellström KE, Hellström I, Nepom JT: Specific blocking factors - Are the important? BBA Rev on Cancer 473: 121–148, 1978.Google Scholar
  59. 59.
    Beyer J-H, Borberg H, Fuchs Ch, and Nagel GA: Plasmapheresis in immunology and oncology, Basel: S Karger, 1982, pp 1–266.Google Scholar
  60. 60.
    North RJ: Cyclophosphamide facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor cells. J Exp Med 55: 1063–1074, 1982.CrossRefGoogle Scholar
  61. 61.
    Hengst RJ: Cyclophosphamide facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor cells. J Exp Med 55: 1063–1074, 1982.Google Scholar
  62. 62.
    Mokyr MB, Hengst JCD, Dray S: Role of antitumor immunity in cyclophosphamide- induced rejection of subcutaneous nonpalpable MOP.315 tumors. Cancer Res 42: 974–979, 1982.PubMedGoogle Scholar
  63. 63.
    Kahan BD, Pellis NR, Lefrue SJ, Tanaka T: Immunotherapeutic effects of tumor-specific transplantation antigens released by 1-butanol. Cancer 49: 1168–1173, 1982.PubMedCrossRefGoogle Scholar
  64. 64.
    Liew FY: Regulation of delayed-type hypersensitivity to pathogens and alloantigens. Immunol Today 3: 18–23, 1982.CrossRefGoogle Scholar
  65. 65.
    Greene MI, Dorf ME, Pierres A, Benacerraf B: Reduction of syngeneic tumor growth by an anti-I-J alloantiserum. Proc Nqt Acad Sci USA 74: 5118–5121, 1977.CrossRefGoogle Scholar
  66. 66.
    Perry LL, Kripke ML, Benacerraf B, Dorf ME, Greene MI: Regulation of the immune response to tumor antigen: VIII. The effects of host specific anti-I-J antibodies on the immune response to tumors of different origin. Cell Immunol 51: 349–359, 1980.PubMedCrossRefGoogle Scholar
  67. 67.
    Fox I J, Perry LL, Sy M-S, Benacerraf G, Greene MI: The influence of ultraviolet irradiation on the system. Clin Imm and Immunopath 16: 141–145, 1980.CrossRefGoogle Scholar
  68. 68.
    Kanno M, Kobayashi S, Tokuhisa T, Takei I, Shinohana N, Taniguchi M: Monoclonal antibodies that recognise the product controlled by a gene of the I-J sub region of the mouse H-2 complex. J EXP Med 54: 1290–1304, 1981.CrossRefGoogle Scholar
  69. 69.
    Waltenbaugh C: Regulation of immune response by I-J products: I. Production and characterization of anti I-J monoclinal antibodies. J Exp Med 154: 1570–1583, 1981.PubMedCrossRefGoogle Scholar
  70. 70.
    Hiramatsu K, Ochi A, Miyatani S, Segawa A, Tada T: Monoclonal antibodies against unique I-region gene products expressed only on mature functional T cells. Nature 296: 600–668, 1982.CrossRefGoogle Scholar
  71. 71.
    Hanna MG, Peters LC: Morphological and functional aspects of active specific immunotherapy of established pulmonary metastases in guinea pigs. Cancer Res 41: 4001–4009, 1981.PubMedGoogle Scholar
  72. 72.
    Yarkoni E, Hunter JT, Sukumar S, Rapp HJ: Active specific immunotherapy of guinea pigs with visceral tumor implants. Cancer Immunol Immunother 12: 273–275, 1982.CrossRefGoogle Scholar
  73. 73.
    Milas L, Scott MT: Antitumor activity of Corynebacterium parvum. Adv Cancer Res 26: 257–260, 1977.CrossRefGoogle Scholar
  74. 74.
    Baldwin RW, Pimm MV: BCG in tumor immunotherapy. Adv Cancer Res 28: 91–147, 1978.PubMedCrossRefGoogle Scholar
  75. 75.
    Pimm MV, Baldwin RW: Immunology and immunotherapy of experimental and clinic metastases. In: Secondary spread cancer, Baldwin RW (ed). London: Academic Press, 1978, pp 163–209.Google Scholar
  76. 76.
    Neri A, Welch D, Kawaguchi T, Nicolson GL: Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. J Natl Cancer Inst 68: 507–517, 1982.PubMedGoogle Scholar
  77. 77.
    Pimm MV, Baldwin RW: Antigenic heterogeneity of primary and metastatic tumors and its implications for immunotherapy. In: Metastatic tumor growth: Cancer campaign 4:305–312. Stuttgart: Gustav Fischer, 1980.Google Scholar
  78. 78.
    Sone S, Poste G, Fidler IJ: Rat alveolar macrophage are susceptible to free and liposome encapsulated lymphokines. J Immunol 124: 2197–2202, 1980.PubMedGoogle Scholar
  79. 79.
    Fidler I J, Sone S. Fogler WE, Barnes ZL: Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78: 1680–1684, 1900.CrossRefGoogle Scholar
  80. 80.
    Fidler IJ, Poste G: Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Seminars in Immunopath 512: 161–174, 1982Google Scholar
  81. 81.
    Baldwin RW, Pimm MV: BCG-mediated responses in tumor immunotheraphy. In: Bacteria and cancer, J. Jeljaszewicz, G. Pulverer, W. Roskowski. London; Academic Press, 205–217, 1982.Google Scholar
  82. 82.
    Baldwin RW, Embleton MJ, Price MR: Monoclonal antibodies specifying tumour-associated antigens and their potential for therapy. Molec Aspects Med 4: 329–368, 1981.CrossRefGoogle Scholar
  83. 83.
    Pimm, MV, Embleton MJ, Perkins AC, Price MR, Robins RA, Robinson GR, Baldwin RW: In vivo localization of anti-osteogenic sarcoma 79IT monoclonal antibody in osteogenic sarcoma xenograft. Int J Cancer 30: 75–85, 1982.PubMedCrossRefGoogle Scholar
  84. 84.
    Baldwin RW, Flannery GR, Pelham JM, Gray JD: Immunomodulation by IFN-conjugated monoclonal antibody to human osteogenic sarcoma. Proc Am Ass Cancer Res 23: 254, 1982.Google Scholar
  85. 85.
    Hellström KE, Hellström I, Brown JP: Human tumor-associated antigens identified by monoclonal antibodies. Seminars in Immunopathol 512: 127–146, 1982.Google Scholar
  86. 86.
    Farrands PA, Perkins AC, Pimm MV, Embleton MJ, Hardy JG, Baldwin RW, Hardcastle JD: Radioimmunodetection of human colorectal cancers using and anti-tumour monoclonal antibody. Lancet 11: 397–400, 1982.CrossRefGoogle Scholar
  87. 87.
    Chatal JF, Saccavini JC, Fumoleau P, Bardy A, Douillard JY, Aubry J, Le Mevel B: Pho- toscanning localization of human tumors using radioiodinated monoclonal antibodies to colorectal carcinoma. J Nucl Med 23: 8, 1982.Google Scholar
  88. 88.
    Sears HF, Mattis J, Herlyn D, Hayry P, Atkinson B, Ernst C, Steplewski Z, Koprowski Hb: Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1: 762–765, 1982.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1983

Authors and Affiliations

  • Robert W. Baldwin

There are no affiliations available

Personalised recommendations